{"id":49660,"date":"2025-09-30T06:30:24","date_gmt":"2025-09-30T04:30:24","guid":{"rendered":"https:\/\/theark.ch\/?p=49660"},"modified":"2025-09-30T06:30:47","modified_gmt":"2025-09-30T04:30:47","slug":"start-up-bioscibex-has-set-up-at-bioark-in-monthey","status":"publish","type":"post","link":"https:\/\/theark.ch\/en\/news\/start-up-bioscibex-has-set-up-at-bioark-in-monthey\/","title":{"rendered":"start-up bioscibex has set up at bioark in monthey"},"content":{"rendered":"\n
la start-up bioscibex, issue d\u2019un laboratoire de recherche de l\u2019epfl et soutenue par la fondation the ark, se donne pour mission de transformer la fabrication des m\u00e9dicaments biologiques. actuellement, le processus de culture cellulaire \u00e0 l\u2019\u00e9chelle commerciale repose sur sept \u00e9tapes cons\u00e9cutives complexes, co\u00fbteuses et sujettes \u00e0 des risques de contamination. avec son bior\u00e9acteur innovant, bioscibex r\u00e9duit ces \u00e9tapes \u00e0 deux, minimisant ainsi les co\u00fbts, les risques de contamination et les erreurs. en d\u00e9veloppement depuis pr\u00e8s d\u2019un an, la technologie de bioscibex vise \u00e0 accompagner l\u2019industrie pharmaceutique vers une production plus efficace et plus s\u00fbre. la jeune pousse vient de s\u2019installer sur le site de bioark \u00e0 monthey, o\u00f9 elle pourra profiter d\u2019un \u00e9cosyst\u00e8me dynamique pour son d\u00e9veloppement.\u00a0<\/strong><\/h5>\n\n

le bior\u00e9acteur de bioscibex<\/a> s\u2019attaque aux probl\u00e9matiques majeures de la fabrication des m\u00e9dicaments biologiques. \u00ab\u2009les entreprises biopharmaceutiques perdent des milliards \u00e0 cause des probl\u00e8mes li\u00e9s aux \u00e9tapes manuelles et aux risques de contamination\u2009\u00bb, explique chlo\u00e9 albietz, co-fondatrice de la start-up. en simplifiant drastiquement le processus, le bior\u00e9acteur r\u00e9duit non seulement les co\u00fbts, mais aussi les risques d\u2019erreurs. avec la preuve de concept d\u00e9sormais valid\u00e9e et trois prototypes finaux pr\u00eats, la start-up se pr\u00e9pare \u00e0 lancer ses premi\u00e8res d\u00e9monstrations aupr\u00e8s des clients. \u00ab\u2009cette \u00e9tape est cruciale pour valider la technologie avant l\u2019\u00e9tape de commercialisation\u2009\u00bb, pr\u00e9cise-t-elle.<\/p>\n\n

le lancement commercial en point de mire<\/strong><\/h5>\n\n

bioscibex se concentre aujourd\u2019hui sur deux objectifs majeurs\u2009: finaliser l\u2019industrialisation de son bior\u00e9acteur et de son consommable, et pr\u00e9parer le lancement du produit sur le march\u00e9. l\u2019entreprise a finalis\u00e9 son premier tour de financement pre-seed. elle d\u00e9bute d\u00e9sormais sa deuxi\u00e8me lev\u00e9e de fonds qui lui permettra de r\u00e9aliser sa premi\u00e8re s\u00e9rie de production pour ses clients. \u00ab\u2009cette lev\u00e9e de fonds est essentielle pour lancer notre produit sur le march\u00e9\u2009\u00bb, souligne chlo\u00e9 albietz. parall\u00e8lement, bioscibex va prochainement renforcer son \u00e9quipe avec l\u2019engagement d\u2019un field application specialist, permettant notamment de supporter les d\u00e9monstrations chez les clients.<\/p>\n\n

bioscibex a int\u00e9gr\u00e9 bioark<\/a>, un \u00e9cosyst\u00e8me propice \u00e0 l\u2019innovation dans le domaine des sciences de la vie. elle a \u00e9galement int\u00e9gr\u00e9 l\u2019incubateur de start-up de la fondation the ark, qui l\u2019aidera dans le d\u00e9veloppement de son innovation, tant du point de vue technique que commercial.<\/p>\n\n

informations compl\u00e9mentaires<\/strong>\u2009: https:\/\/bioscibex.com<\/a><\/p>\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

start-up bioscibex, which grew out of an epfl research laboratory, is on a mission to transform the manufacture of biological medicines. currently, the commercial-scale cell culture process involves seven complex, costly and contamination-prone steps. however, with its innovative bioreactor, bioscibex reduces these steps to two, thereby minimising costs, contamination risks and errors. in development for almost a year, the technology aims to help the pharmaceutical industry move towards safer and more efficient production. the start-up has just moved into the bioark site in monthey, where it will benefit from a dynamic ecosystem to support its development.<\/p>\n","protected":false},"author":3,"featured_media":49655,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[210],"tags":[],"class_list":["post-49660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-sciences-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/49660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/comments?post=49660"}],"version-history":[{"count":10,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/49660\/revisions"}],"predecessor-version":[{"id":50103,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/49660\/revisions\/50103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media\/49655"}],"wp:attachment":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media?parent=49660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/categories?post=49660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/tags?post=49660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}